3rd DCT, HYBRID & CENTRALISED CLINICAL TRIALS WORLD CONGRESS 2027 EUROPE
Where Innovation, Collaboration and Human‑Centred Design Meet to Transform Clinical Research
Thursday 25th - Friday 26th February 2027
Facilitate Live is very pleased to welcome you to our upcoming 3rd Decentralized, Hybrid, Centralised Clinical Trials World Congress 2027 Europe.
The 3rd DCT, Hybrid & Centralised Trials World Congress 2027 Europe brings together a global community united by a common purpose: to shape a future where clinical research is more accessible, more connected and more responsive to the needs of people everywhere. At a time when healthcare is evolving rapidly and expectations around participation, transparency and innovation continue to rise, this Congress offers a space for reflection, collaboration and forward‑looking ambition.
Across two days, leaders from every corner of the research ecosystem will gather not simply to discuss new approaches, but to imagine what is possible when diverse perspectives come together. Whether representing pharma, biotech, CROs, academic institutions, patient organisations or government agencies, each participant contributes a vital piece of the broader vision. The Congress celebrates this diversity of expertise, recognising that meaningful progress in clinical research can only be achieved when all voices are heard and valued.
The programme will explore how modern trial models can be shaped to better serve science and society. It will encourage attendees to look beyond individual technologies or operational processes and instead consider the bigger picture: how we design studies that are more inclusive, how we build systems that are more resilient, and how we create experiences that respect and empower the people who participate. The conversations throughout the event will highlight the importance of flexibility, empathy and shared responsibility in advancing research that truly reflects the world it aims to improve.
A central theme of the Congress is the belief that innovation is not only about new tools, but about new ways of thinking. As digital capabilities expand and remote approaches become more common, the opportunity emerges to rethink long‑standing assumptions about how trials must operate. This gathering encourages attendees to embrace curiosity, challenge convention and explore how modern methods can coexist with trusted foundations. It is an invitation to imagine trial models that are both scientifically rigorous and deeply human‑centred.
Equally important is the recognition that trust and transparency are essential to the future of research. As trials evolve, so must the ways we communicate, engage and collaborate with participants and communities. The Congress emphasises the importance of listening, truly listening, to the experiences, concerns and aspirations of patients. Their voices guide the direction of innovation and remind us that every advancement ultimately serves individuals and families seeking hope, healing and progress.
Throughout the event, attendees are encouraged to connect, share and build relationships that extend beyond the Congress itself. The challenges facing clinical research are complex, but they are also shared. By working together, across sectors, disciplines and borders, we can create trial ecosystems that are more inclusive, more efficient and more capable of meeting the needs of a changing world.
The 3rd DCT, Hybrid & Centralised ClinicalTrials World Congress 2027 Europe is more than a meeting. It is a collective commitment to shaping a future where research is accessible, equitable and grounded in collaboration. It is a celebration of what we can achieve when we unite around a shared vision:
advancing clinical trials that honour both scientific excellence and the people at the heart of every study
We look forward to welcoming you to the 3rd Decentralized, Hybrid, Centralised Clinical Trials World Congress 2027 Europe.
Sincerely yours,
Jocelyn Raguindin
Conference Director
Facilitate Live
Gain The Latest Insights On:
- Evolving clinical trial models that blend decentralised, hybrid and traditional approaches with purpose and flexibility
- Designing participant‑centred studies that strengthen trust, accessibility and engagement
- Digital tools and remote approaches that enhance convenience, connection and data richness
- Cross‑sector collaboration that unites industry, academia, patient groups and public‑sector partners
- Operational strategies that improve consistency, quality and resilience across global research networks
- Modern data collection and oversight practices for an increasingly digital
research landscape - Innovative thinking that challenges convention and inspires more inclusive trial design
- Approaches that support sites and investigators as they adapt to new
technologies and workflows - Communication and transparency practices that deepen participant
confidence and understanding - Opportunities to expand participation through flexible pathways and accessible digital touchpoints
- Shared frameworks that help organisations navigate change while maintaining scientific integrity
- New ways to integrate digital capabilities into long‑term research strategies and portfolios
- Emerging trends shaping the future of global clinical trial delivery and operational excellence
- Collective momentum toward a more connected, equitable and future‑ready clinical research ecosystem
Sponsorship & Exhibit Opportunities
Our event partners and team of experts are recognized for creating and providing unique, innovative events. We open doors and create access to business opportunities for our clients. Our events are forum for discussion, learning, showcasing new technologies, innovations, new products and trends, solutions and concepts.
The impact you make and how you get your message across at our Facilitate Live Events is up to you – we offer packages or tailor made solutions to meet your exact requirements and budget.
By sponsoring a Facilitate Live Event you will be exposed to the following:
- Access to key decision makers
- Direct access to our delegates and attendees
- Increase worldwide awareness of your organisations latest products and services
- Drive and create new business opportunities
- Generate new contacts and renewed interest for your product of expertise
- Be recognised as a key player and a key supporter of your industry sector
- Demonstrate your organization’s commitment
- Demonstrate your excellence as a technical supplier
- Show brand awareness and brand building
- Brand and product endorsements
- Extensive pre-show and post-show coverage
Solution Showcase
Showcase your latest cutting-edge solutions, new products, technology, innovations and trend. Meet face to face with high level decision makers who are in a receptive mindset and actively seeking solutions and services.
As an exhibitor you will gain access to this exclusive captive audience and have the opportunity to:
- Speak to the attendees and demonstrate your product / services at the solution showcase network to captive and receptive key decision makers
- Gain exposure to one of our Facilitate Live
- Host a networking drinks reception or lunch for attendees
- Meet one-on-one with attendees
- Generate a high number of leads with senior decision makers
- Meet your peers and exhibit alongside your competitors
- Present case studies and in-depth information in a solution provider showcase session
- Present case studies and in-depth information in a solution provider showcase session
- Educate the market with your product and technology solutions
Sponsorship & Exhibit Inquiries
Email: Sponsor@facilitatelive.com Tel No: +44 (0)207 193 3485
Who Should Attend:
This Congress will provide information to pharmaceutical and biotech companies, researchers, physicians, institutional review boards (IRBs), patient organizations and advocates, and regulatory agencies about the implementation of Real-World Evidence.
Network with members of the boards, VP’s, Directors, Heads/Chiefs, and Senior Managers of leading Pharmaceuticals and Biotech Companies, Government, CRO’s and Solution Providers Involved in:
Pharma & Biotech
- Heads of Clinical Operations
- Directors of R&D and Clinical Development
- VPs / SVPs of Digital Health & Innovation
- Clinical Trial Strategy Leads
- Medical Directors & Therapeutic Area Heads
- Heads of Patient Engagement & Diversity
- Digital Transformation Leaders
- Evidence Generation & Data Science Leads
Academic & Research Institutions
- Principal Investigators
- Clinical Research Coordinators
- Professors of Clinical Trial Methodology
- Digital Health Researchers
- Biostatisticians & Methodology Experts
- Research Ethics & Governance Leads
Patient Organisations
- Patient Advocacy Leaders
- Community Engagement Managers
- Patient Advisory Board Members
Diversity, Equity & Inclusion Specialists
Government & Public‑Sector Agencies
- Regulatory Affairs Leaders
- Health Policy Advisors
- Digital Health Programme Directors
- Public Health Innovation Managers
- National Research Infrastructure Leads
Technology & Digital Health Innovators
- Founders & CEOs of Digital Health
Companies - Product Leaders in eCOA, eConsent, Wearables & Data Platforms
- AI & Machine Learning Leads
- Patient Experience Designers
CROs & Service Providers
- Clinical Operations Directors
- Project & Programme Leaders
- Digital Trial Delivery Specialists
- Global Study Managers
- Data Management & Analytics Leads
- Patient Recruitment & Retention Strategists
- Technology & Platform Integration Heads
- Global Marketing
- Consultans
- And much more…
Co-located with Patient Centricity & Collaboration World Congress 2027 Europe.
Joint Networking & Exhibit Area.
Website: www.patientcentricityworld.com
Strategy, Regulation & Patient‐Centric Transformation
- Integrating decentralised, hybrid and centralised approaches into a cohesive future‐ready ecosystem.
- Regulatory expectations that influence digital trial design, remote data capture, and the operational frameworks required for compliance.
- Patient‐driven priorities that shape protocol flexibility, technology usability, and the overall experience of participating in digitally‐enabled trials.
- Collaboration models that allow pharma, CROs, tech providers and regulators to accelerate modernisation.
Moderator:
Van Zyl Engelbrecht, Head of Country Operations, UK, Alexion Pharmaceuticals
Panellists:
Lewis Millen, Head of Clinical Innovation and Digital Solutions, UCB
Robert Mitchell-Thain, CEO, PBC Foundation
- Reviewing evolving guidance on digital consent, telemedicine and remote monitoring.
- Navigating cross‐border compliance challenges in multinational decentralised trials.
- Assessing regulator perspectives on patient‐generated data and digital endpoints.
- Outlining future frameworks that will shape digital trial innovation.
Khadija Rantell, Senior Statistical Assessor, MHRA
- Determining when decentralisation adds value versus when centralisation is essential.
- Evaluating digital tools across therapeutic areas for measurable operational gains.
- Considering budgeting, ROI and resource allocation for digital transformation.
- Building internal capabilities to support scalable hybrid trial execution.
Adama Ibrahim, VP, Head of R&D Digital and AI, Lundbeck
- Redesigning workflows to support seamless coordination between remote and on‐site activities.
- Staff training frameworks that build confidence in digital tools and ensure consistent execution across sites.
- Addressing multi‐vendor complexity and the operational challenges associated with fragmented technology.
- Maintaining data quality and protocol adherence across decentralised modalities and diverse patient environments.
- Streamlining data flows across eCOA, eConsent, wearables and telemedicine.
- Reducing site burden through automation and integrated workflows.
- Real‐time monitoring tools that enhance operational visibility, enabling proactive issue resolution and improved trial predictability.
- Vendor collaboration models that support scalability, reduce fragmentation and strengthen long‐term digital infrastructure.
CONFIRMED-ALLOCATED: Awaiting for Company profile
- Exploring design principles that ensure digital platforms are intuitive, accessible and inclusive
- Improving adherence through personalised digital engagement.
- Simplifying remote procedures to reduce patient burden enabling high‐quality data capture and safety oversight.
- How patient‐centric digital tools improve recruitment outcomes and broaden access to diverse populations?
CONFIRMED-ALLOCATED: Awaiting for Company profile
- The journey from individual DCT experiences to a nationally shared knowledge resource.
- Building effective public-private collaboration around clinical trial innovation.
- Capturing lessons learned from multiple DCT elements and stakeholders.
- Making DCT implementation easier, faster and more predictable.
- How the Swedish model can be adapted and reused in other countries.
Mats Thoring, Site Management DCT Advisor, Pharmaceuticals Division, Bayer AB
For many people living with chronic health conditions, observation, monitoring, sampling, data collection and analysis
are familiar actions. Their lived expertise can:
- Identify what is practical, preferable, tolerable and acceptable in terms of trial participation
- Identify the impact, burden or disruption of participation to how they live with their condition/s
- Directly inform innovative trial design with potential to improve recruitment and how they would live with participation
- Identify aspects of participation and trial delivery that could be integrated into decentralised, remote or hybrid design
- Provide perspective on consistency and integrity of data capture, safety and monitoring
- Provide foresight early in product development, establishing the logistical considerations associated with formulation, dosing, storage and delivery mechanisms
- Demonstrate how familiarity through chronic health management can influence industry requirements for
innovative trial design
Lorna Allen, Community Engagement and Involvement Lead, Cystic Fibrosis Trust
- Identifying digital literacy gaps across patient communities and strategies to support individuals with limited technology experience.
- Co‐designing protocols with patient groups for more practical, usable and inclusive trial experiences.
- Exploring accessibility considerations for rare disease, mobility‐limited and geographically remote patients.
- Approaches that strengthen trust and empower patients throughout digitally‐enabled participation.
Allocated / Reserved
- Predictive analytics tools that identify emerging safety signals earlier and support proactive intervention strategies.
- Automated remote assessment workflows to reduce manual burden and improve consistency in safety monitoring.
- Integrating AI outputs into regulatory‐compliant processes without compromising oversight or data integrity.
- Patient‐experience improvements enabled by timely, personalised safety interventions
Maria Bowen, Global Head, Protocol Excellence, Sr. Director, Clinical Science, Daiichi Sankyo US
- How sites balance remote responsibilities with traditional on‐site activities while maintaining operational efficiency.
- Addressing technology overload and presenting strategies for platform consolidation that reduce complexity.
- Digital competency programmes that equip site staff with the skills needed to manage modern trial technologies.
- Best practices for maintaining high‐quality data capture and patient engagement in hybrid environments.
Heather Phillips, Associate Director, Study Site Engagement Lead, Boehringer Ingelheim
- Combining regulatory evolution, hybrid strategy and patient priorities into a unified direction for digital trials.
- Integrating interoperability, technology consolidation and site readiness to strengthen operational foundations.
- Translating academic evidence and public‐sector initiatives into practical frameworks for scalable decentralised research.
- Building long‐term alignment across sponsors, CROs, tech providers, patients and regulators to support sustainable transformation.
Moderator:
Panellists:
Rasmus Hjorth, Head of Communication, James Lind Care
Svetlana Karova, Manager, Clinical Risk and Analytics, Alnylam*
Implementation, Technology & Real‐World Delivery
- Our Past Trials PRINCIPLE and PANORAMIC
- Our Present Trial: ECRAID-Prime (30 mins) (Logistics, Recruitment and consent, Pharmacy)
- Our Future Trial: PREPARED
Bernadette Mundy, Senior Clinical Research Nurse
Emma Harper, Project Manager
Andrew Fairbairn, Clinical Researcher (General Practitioner)
Lucy Cureton, Senior Clinical Trial Manager
Mona Koshkouei, Head of GMP Operations, Principal Pharmacist
Dr Emily Bongard, Head of Operations,
Nuffield Department of Primary Care Health Sciences, University of Oxford
- Lessons learned from real‐world decentralised and hybrid deployments across multiple therapeutic areas and geographies.
- Deviations and variability introduced by remote data sources, including device inconsistencies and patient behaviour.
- Site‐centric approaches to digital workflow integration that reduce burden and improve operational clarity.
- Strategies to ensure patient safety and data integrity in remote and hybrid trial environments.
Moderator:
Dr Viraj Rajadhyaksha, Head Global Partnerships & Global Medical Ethics, AstraZeneca
Panellists:
Karina Morley, Global Head Research Innovation & Strategic Alliances BPM, AstraZeneca
Kayuri Odedra, Associate Director, Patient Inclusion, EMEA Region, Abbvie
- How decentralisation enables faster early‐phase studies and more agile operational models for small teams.
- Digital recruitment strategies tailored to niche, rare and geographically dispersed patient populations.
- Cost‐efficiency gains achieved through remote procedures, simplified workflows and reduced site dependency.
- Partnership models that allow biotech organisations to leverage CRO and technology expertise effectively.
Confirmed Allocated – Awaiting for details
- How AI can optimise protocol feasibility, reduce patient burden and improve operational predictability.
- Emerging digital biomarkers and remote assessment technologies that expand the scope of measurable endpoints.
- Predictive recruitment and retention models that support more accurate planning and resource allocation.
- Regulatory considerations for AI‐supported decision‐making and the validation of algorithmic outputs.
CONFIRMED-ALLOCATED: Awaiting for Company profile
- Operational models that support multi‐country decentralised studies with consistent quality and oversight.
- Regulatory variability across regions and strategies for harmonising digital processes internationally.
- Technology harmonisation approaches that reduce fragmentation and improve operational efficiency.
- Lessons learned from large‐scale deployments across diverse therapeutic areas.
- How to define strategic drug development
- Unmet clinical and patients need are the starting point
- Translating and breakthrough technology into a clinical and patients value
- Evidence-driven decisions
- Focus on patients impact
Dr. Najy Alsayed, Global Therapeutic Area Head, A. Menarini Pharma
- Introducing eSource and its role in connecting routine care with clinical research.
- Advancing adoption through the i~HD eSource Scale-up Task Force.
- Applying the eSource Playbook: from site readiness to implementation and scaling.
- Learning from five oncology centres: coordinator experience and evidence to support wider adoption.
Mats Sundgren, Senior Industry Scientific Director & Co-founder, European Institute, i-HD
- Communication strategies that clearly explain digital trial expectations and reduce uncertainty.
- Support models that help patients navigate remote participation challenges with confidence.
- How co‐creation strengthens trust and improves the relevance of digital trial tools.
- Approaches to ensure equitable access to digital platforms across diverse populations.
Vesela Aleksandrova, Senior Director Clinical Operations, Shionogi Europe
- AI‐driven automation tools that reduce manual burden and streamline operational processes.
- Intelligent scheduling and remote visit optimisation features that improve trial efficiency.
- How workflow intelligence enhances predictability and reduces operational risk.
- Collaboration models that align technology innovation with sponsor and CRO needs.
Joanna Bell, Programme Lead, Sustainable Healthcare Coalition
Carly Santer, Strategic Advisor, Healthcare Decarbonisation, Sustainable Healthcare Coalition
Dr Fiona Adshead, Chair, Sustainable Healthcare Coalition
- Combining insights from AI‐driven design, digital biomarkers and remote monitoring to shape next‐generation methodologies.
- Aligning biotech agility, CRO global scaling and pharma transformation to build unified operational models.
- Strengthening patient trust through transparent communication and inclusive digital engagement practices.
- Translating unified data platforms, automation and national policy into sustainable digital ecosystems.
Moderator:
Panelists:
